Last reviewed 2026-04-20 · How we verify

ramosetron with dexamethasone

Ramosetron with dexamethasone, marketed by Yonsei University, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk is the potential increase in competition following the patent expiry.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Acupuncture for Chemotherapy-Induced Nausea and Vomiting (NA)
• The Different Effectiveness of Single Acupoint（PC6 or CV12) vs Matching Acupoints(PC6 and CV12) in Chemotherapy-induced Nausea and Vomiting (NA)
• Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone (PHASE4)
• The Comparative Study on the Efficacy and Safety of Single Acupoint and Matching Acupoints (NA)
• A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea (PHASE3)
• Post-operative Nausea Vomiting in Laparoscopic Cholecystectomy (PHASE4)
• Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in Chemotherapy-induced Nausea and Vomiting (NA)
• Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.